Phase I/II evaluation of safety and efficacy of rexin-G for recurrent or metastatic pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Jun 2011
At a glance
- Drugs Rexin-G (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 24 May 2010 Results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting, according to a Epeius Biotechnologies media release.